Warning: The NCBI web site requires JavaScript to function. more...
Early recombinant activated factor VII for intracerebral hemorrhage reduced hematoma growth and mortality, while improving functional outcomes.
Emlet LL, Crippen D.
Crit Care. 2006 Feb;10(1):304. Review. No abstract available.
Related citations
Recombinant activated factor VII for acute intracerebral hemorrhage.
Mayer SA.
Stroke. 2007 Feb;38(2 Suppl):763-7. Review.
Friedrich JO.
N Engl J Med. 2005 May 19;352(20):2133-4; author reply 2133-4. No abstract available.
[Acute treatment with recombinant factor VII is probably indicated for intracerebral haematoma].
Rinkel GJ.
Ned Tijdschr Geneeskd. 2005 Aug 13;149(33):1827-9. Dutch.
Timing is everything in intracerebral hemorrhage.
Steiner T, Broderick J, Brun NC, Davis SM, Diringer MN, Mayer S, Skolnick BE.
Stroke. 2008 Jul;39(7):e117-8; author reply e119-20. Epub 2008 May 22. No abstract available.
Ultra-early hemostatic therapy for acute intracerebral hemorrhage.
Mayer SA, Rincon F.
Semin Hematol. 2006 Jan;43(1 Suppl 1):S70-6.
Medical management of acute intracerebral hemorrhage.
Anderson CS.
Curr Opin Crit Care. 2009 Apr;15(2):93-8. Review.
A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia.
Yuan ZH, Jiang JK, Huang WD, Pan J, Zhu JY, Wang JZ.
J Clin Neurosci. 2010 Jun;17(6):685-93. Review.
Early recombinant factor VIIa therapy in acute intracerebral hemorrhage: promising approach.
Kumar S, Badrinath HR.
Neurol India. 2006 Mar;54(1):24-7. Review.
Reducing the risk of ICH enlargement.
Wartenberg KE, Mayer SA.
J Neurol Sci. 2007 Oct 15;261(1-2):99-107. Epub 2007 Jul 12. Review.
Multiple ischemic strokes associated with use of recombinant activated factor VII.
Libman RB, Lungu C, Kwiatkowski T.
Arch Neurol. 2007 Jun;64(6):879-81.
Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII.
Steiner T, Diringer MN, Schneider D, Mayer SA, Begtrup K, Broderick J, Skolnick BE, Davis SM.
Neurosurgery. 2006 Oct;59(4):767-73; discussion 773-4.
Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage.
Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators.
Neurology. 2006 Apr 25;66(8):1175-81.
Hemostatic treatment in the early stage of intracerebral hemorrhage: the recombinant factor VIIa experience.
Kase CS.
Stroke. 2005 Oct;36(10):2321-2. Epub 2005 Sep 8. Review. No abstract available.
The effect of activated factor VII for intracerebral hemorrhage beyond 3 hours versus within 3 hours.
Hallevi H, Gonzales NR, Barreto AD, Martin-Schild S, Albright KC, Noser EA, Illoh K, Khaja AM, Allison T, Escobar MA, Shaltoni HM, Grotta JC.
Stroke. 2008 Feb;39(2):473-5. Epub 2008 Jan 3.
Update on medical and surgical management of intracerebral hemorrhage.
Cheung RT.
Rev Recent Clin Trials. 2007 Sep;2(3):174-81. Review.
Chang GY.
Neurology. 2007 Feb 6;68(6):471-2; author reply 472. No abstract available.
Treatment of acute intracerebral hemorrhage.
Auriel E, Bornstein NM.
Isr Med Assoc J. 2006 Nov;8(11):812-4. Review. No abstract available.
Intracerebral hemorrhage--improving outcome by reducing volume?
Tuhrim S.
N Engl J Med. 2008 May 15;358(20):2174-6. No abstract available.
Ultra-early hemostatic therapy for primary intracerebral hemorrhage: a review.
Can J Neurol Sci. 2005 Dec;32 Suppl 2:S31-7. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on